Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2024-07-11 00:00:00 ET · period of report 2024-07-09 · accession 0001746473-24-000119 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-11 | 2024-07-09 | PLRX | Lefebvre Eric | Chief Medical Off | A - Grant | $0.00 | +24.1K | 225.4K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-09 | A | A | 24,063 | $0.00 | 225,371 | D | — | — | (F1) On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares. (F2) Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. |